AU2011204425A1 - Method for treatment of inflammatory disease and disorder - Google Patents
Method for treatment of inflammatory disease and disorder Download PDFInfo
- Publication number
- AU2011204425A1 AU2011204425A1 AU2011204425A AU2011204425A AU2011204425A1 AU 2011204425 A1 AU2011204425 A1 AU 2011204425A1 AU 2011204425 A AU2011204425 A AU 2011204425A AU 2011204425 A AU2011204425 A AU 2011204425A AU 2011204425 A1 AU2011204425 A1 AU 2011204425A1
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- seq
- inflammatory
- administered
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 81
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 66
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 95
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 84
- 239000003112 inhibitor Substances 0.000 claims description 170
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 145
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 78
- 229920001184 polypeptide Polymers 0.000 claims description 67
- 201000004681 Psoriasis Diseases 0.000 claims description 44
- 201000006417 multiple sclerosis Diseases 0.000 claims description 39
- 230000002757 inflammatory effect Effects 0.000 claims description 35
- 206010012601 diabetes mellitus Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 231100000753 hepatic injury Toxicity 0.000 claims description 2
- 201000006334 interstitial nephritis Diseases 0.000 claims description 2
- 208000001875 irritant dermatitis Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000011191 terminal modification Methods 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 59
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 59
- 239000000203 mixture Substances 0.000 abstract description 36
- 101150020891 PRKCA gene Proteins 0.000 description 127
- 210000002510 keratinocyte Anatomy 0.000 description 107
- 230000028327 secretion Effects 0.000 description 105
- 102000004127 Cytokines Human genes 0.000 description 98
- 108090000695 Cytokines Proteins 0.000 description 98
- 210000003491 skin Anatomy 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 60
- 208000027418 Wounds and injury Diseases 0.000 description 56
- 206010052428 Wound Diseases 0.000 description 55
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 52
- 239000012190 activator Substances 0.000 description 51
- 230000000694 effects Effects 0.000 description 48
- 108700012920 TNF Proteins 0.000 description 42
- 230000004054 inflammatory process Effects 0.000 description 40
- 206010061218 Inflammation Diseases 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 238000009472 formulation Methods 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 28
- 102100027765 Atlastin-2 Human genes 0.000 description 27
- 101710192135 Atlastin-2 Proteins 0.000 description 27
- 108090001061 Insulin Proteins 0.000 description 27
- 102000004877 Insulin Human genes 0.000 description 27
- 229940125396 insulin Drugs 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 26
- 230000004069 differentiation Effects 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 210000002540 macrophage Anatomy 0.000 description 23
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 22
- -1 PKCr Proteins 0.000 description 22
- 208000003251 Pruritus Diseases 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 238000001994 activation Methods 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 230000008595 infiltration Effects 0.000 description 18
- 238000001764 infiltration Methods 0.000 description 18
- 230000035876 healing Effects 0.000 description 17
- 201000002491 encephalomyelitis Diseases 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 230000000770 proinflammatory effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 15
- 108010002352 Interleukin-1 Proteins 0.000 description 14
- 102000000589 Interleukin-1 Human genes 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 230000028709 inflammatory response Effects 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001185 psoriatic effect Effects 0.000 description 12
- VBMOHECZZWVLFJ-GXTUVTBFSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]hexan Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN VBMOHECZZWVLFJ-GXTUVTBFSA-N 0.000 description 11
- 229960001340 histamine Drugs 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 108010068904 lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine Proteins 0.000 description 11
- 210000004927 skin cell Anatomy 0.000 description 11
- QPIROHVZMLYRNN-YRNJLPRFSA-N 2-[(3s,6s,9s,12s,15r)-15-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-9-benzyl-6-[(2s)-butan-2-yl]-3-(2-methylsulfanylethyl)-2,5,8,11,14-pentaoxo-1-thia-4,7,10,13-tetrazacyclohe Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCSC)C(=O)SC[C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 QPIROHVZMLYRNN-YRNJLPRFSA-N 0.000 description 10
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 9
- 102000015696 Interleukins Human genes 0.000 description 9
- 108010063738 Interleukins Proteins 0.000 description 9
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 9
- 108010070514 Keratin-1 Proteins 0.000 description 9
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 102100039558 Galectin-3 Human genes 0.000 description 8
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 description 8
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 8
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 8
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 210000000245 forearm Anatomy 0.000 description 8
- 238000011532 immunohistochemical staining Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000006386 Myelin Proteins Human genes 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102100028314 Filaggrin Human genes 0.000 description 6
- 101710088660 Filaggrin Proteins 0.000 description 6
- 102000003996 Interferon-beta Human genes 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 102100031784 Loricrin Human genes 0.000 description 6
- 102000042846 PKC family Human genes 0.000 description 6
- 108091082203 PKC family Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000009172 bursting Effects 0.000 description 6
- 210000001339 epidermal cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229960001388 interferon-beta Drugs 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 108010079309 loricrin Proteins 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 229960001052 streptozocin Drugs 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102100028571 Disabled homolog 2-interacting protein Human genes 0.000 description 5
- 101710191399 Disabled homolog 2-interacting protein Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 108010005716 Interferon beta-1a Proteins 0.000 description 5
- 101710137272 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101150010978 PRKCE gene Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000037313 granulation tissue formation Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007115 recruitment Effects 0.000 description 5
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 108010066321 Keratin-14 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229940003504 avonex Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229940021459 betaseron Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 229940038717 copaxone Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229940038850 rebif Drugs 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229940079023 tysabri Drugs 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 3
- 108050003188 Disks large-associated protein 1 Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101150001670 PRKCG gene Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 3
- 102100037339 Protein kinase C epsilon type Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 125000000539 amino acid group Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 238000011138 biotechnological process Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- NVLDXKCJZRQSDJ-UHFFFAOYSA-L cyclohexane-1,2-diamine;2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-olate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.OCC(O)C1OC(=O)C([O-])=C1O.OCC(O)C1OC(=O)C([O-])=C1O NVLDXKCJZRQSDJ-UHFFFAOYSA-L 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000007658 neurological function Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 206010000349 Acanthosis Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 102000013266 Human Regular Insulin Human genes 0.000 description 2
- 108010090613 Human Regular Insulin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010021519 Impaired healing Diseases 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102000005706 Keratin-6 Human genes 0.000 description 2
- 108010070557 Keratin-6 Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 206010027925 Monoparesis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003776 glatiramer acetate Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940103471 humulin Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IHPBUIGQYZNWCV-YWLUFSBHSA-N (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-3-phenyl-2-(tetradecanoylamino)propanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCC)CC1=CC=CC=C1 IHPBUIGQYZNWCV-YWLUFSBHSA-N 0.000 description 1
- UCADRBIEWWELGN-PGMVXXSLSA-N (2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-6-amino-2-(tetradecanoylamino)hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UCADRBIEWWELGN-PGMVXXSLSA-N 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- ZGWVBIWGEZHQAM-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate methyl 4-hydroxybenzoate 1-phenoxyethanol propane-1,2-diol propane-1,2,3-triol Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)OCC(O)CO.O(C1=CC=CC=C1)C(C)O.COC(=O)C1=CC=C(O)C=C1.C(C(C)O)O.OCC(O)CO ZGWVBIWGEZHQAM-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 101100181138 Drosophila melanogaster Pkc98E gene Proteins 0.000 description 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014201 Eczema nummular Diseases 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010054923 Inflammation of wound Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 101100070645 Mus musculus Hint1 gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 108700043304 PKC-3 Proteins 0.000 description 1
- 101150036732 PRKCQ gene Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102100021557 Protein kinase C iota type Human genes 0.000 description 1
- 101710201186 Protein kinase C-like 1 Proteins 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002878 effect on pruritus Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000000015 environmental pathogen Species 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 108010085520 epsilonV1-2 peptide Proteins 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000028266 oligodendrocyte apoptotic process Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940075461 other therapeutic product in atc Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000014235 psoriasis 9 Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 208000033002 susceptibility to psoriasis 1 Diseases 0.000 description 1
- 208000032273 susceptibility to psoriasis 9 Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012216534A AU2012216534A1 (en) | 2010-01-11 | 2012-08-30 | Method for treatment of inflammatory disease and disorder |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29379410P | 2010-01-11 | 2010-01-11 | |
| US61/293,794 | 2010-01-11 | ||
| US40550910P | 2010-10-21 | 2010-10-21 | |
| US61/405,509 | 2010-10-21 | ||
| PCT/IL2011/000034 WO2011083483A2 (en) | 2010-01-11 | 2011-01-11 | Method for treatment of inflammatory disease and disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012216534A Division AU2012216534A1 (en) | 2010-01-11 | 2012-08-30 | Method for treatment of inflammatory disease and disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2011204425A1 true AU2011204425A1 (en) | 2012-08-02 |
Family
ID=44305895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011204425A Abandoned AU2011204425A1 (en) | 2010-01-11 | 2011-01-11 | Method for treatment of inflammatory disease and disorder |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8349793B2 (https=) |
| EP (3) | EP2523677A2 (https=) |
| JP (2) | JP2013516500A (https=) |
| CN (2) | CN103083669A (https=) |
| AU (1) | AU2011204425A1 (https=) |
| CA (2) | CA2789972A1 (https=) |
| RU (2) | RU2012133148A (https=) |
| WO (3) | WO2011083481A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| EP2452686A3 (en) | 2005-08-29 | 2012-09-05 | HealOr Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| AU2011327785A1 (en) * | 2010-11-08 | 2013-03-07 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
| WO2014041537A1 (en) * | 2012-09-13 | 2014-03-20 | Healor Ltd. | Protein kinase c (pkc) alpha inhibitors for treatment and prevention of toxicities caused by radiation |
| WO2014179491A2 (en) | 2013-04-30 | 2014-11-06 | La Jolla Institute For Allergy And Immunology | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-η |
| KR20170040132A (ko) | 2014-06-02 | 2017-04-12 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Fc 단편의 제조 |
| US10328114B2 (en) * | 2014-10-28 | 2019-06-25 | University Of Iowa Research Foundation | Lung injury repair compositions and methods |
| WO2019116096A1 (en) | 2017-12-15 | 2019-06-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549747A (en) | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| US3856919A (en) | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3947573A (en) | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
| US3767788A (en) | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767789A (en) | 1971-06-21 | 1973-10-23 | Burton Parsons & Co Inc | Method of providing a synthetic mucus in vivo |
| US3987163A (en) | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
| US3907985A (en) | 1973-07-27 | 1975-09-23 | Burton Parsons And Company Inc | Polystyrene sulfonate containing opthalmic solutions |
| US4029817A (en) | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
| US3920810A (en) | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
| US4120949A (en) | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4558033A (en) | 1983-06-06 | 1985-12-10 | Amgen | Potentiation of the effects of insulin by peptides |
| US4673649A (en) | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
| WO1985005036A1 (en) | 1984-04-30 | 1985-11-21 | The Trustees Of Columbia University In The City Of | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
| DE3674883D1 (de) | 1985-11-25 | 1990-11-15 | Wako Pure Chem Ind Ltd | Farbentwicklungsmethode in klinischen untersuchungen. |
| US4833257A (en) | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| JPH0739508B2 (ja) | 1986-11-11 | 1995-05-01 | 株式会社林原生物化学研究所 | プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途 |
| US4885163A (en) | 1987-02-24 | 1989-12-05 | Eli Lilly And Company | Topical use of IGF-II for wound healing |
| US4808402A (en) | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| JPS63303929A (ja) | 1987-06-04 | 1988-12-12 | Kanji Izumi | 創傷治療剤 |
| US5700450A (en) | 1988-03-30 | 1997-12-23 | The Trustees Of Boston University | Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof |
| ZA892928B (en) | 1988-04-25 | 1991-01-30 | Pro Neuron Inc | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
| US5137734A (en) | 1989-03-22 | 1992-08-11 | Dana Farber Cancer Institute | Angiogenic monoglycerides |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5158935A (en) | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
| US5723119A (en) | 1989-07-28 | 1998-03-03 | Schering Corporation | Method for enhancing wound healing/repair with IL-4 |
| US5145679A (en) | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
| US5423778A (en) | 1989-12-14 | 1995-06-13 | Elof Eriksson | System and method for transplantation of cells |
| US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
| CA2108146A1 (en) | 1991-04-11 | 1992-10-12 | Stuart W. Mccombie | Anti-tumor and anti-psoriatic agents |
| AU668509B2 (en) | 1991-04-19 | 1996-05-09 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| JPH0543453A (ja) | 1991-08-20 | 1993-02-23 | Sumitomo Pharmaceut Co Ltd | 創傷治癒促進用局所用徐放性製剤 |
| US5591709A (en) | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| HUT67319A (en) | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| AU3062392A (en) | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
| US5948898A (en) * | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| DE4208552A1 (de) | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
| GB9210574D0 (en) | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| CA2125060C (en) | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| US6485721B1 (en) | 1994-04-25 | 2002-11-26 | Research Development Corporation Of Japan | Biologically active substance-secreting hybrid gel |
| US6028118A (en) | 1996-08-08 | 2000-02-22 | Les Laboratoires Aeterna Inc. | Methods of using extracts of shark cartilage |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| RU2198900C2 (ru) | 1994-05-24 | 2003-02-20 | Еда Рисерч энд Дивелопмент Ко., Лтд. | Усовершенствованный сополимер-1 и способ его получения |
| JPH07316066A (ja) | 1994-05-26 | 1995-12-05 | Mochida Pharmaceut Co Ltd | 創傷治癒剤 |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5631245A (en) | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
| DK0877752T3 (da) | 1996-01-23 | 2003-09-15 | Univ Leland Stanford Junior | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler |
| IL126873A (en) * | 1996-05-30 | 2005-09-25 | Aventis Pharma Inc | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
| US5869037A (en) | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
| JPH10158188A (ja) | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| GB9702943D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
| JPH10265405A (ja) | 1997-03-19 | 1998-10-06 | Masaaki Nanbara | インスリン含有の皮膚外用製剤 |
| US6274712B1 (en) | 1997-12-23 | 2001-08-14 | 3-Dimensional Pharmaceuticals, Inc. | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 |
| FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| US6489306B2 (en) | 1998-02-23 | 2002-12-03 | University Of South Florida | Method of intranasal gene transfer for protection against respiratory infection |
| US6335201B1 (en) | 1998-03-06 | 2002-01-01 | The Regents Of The University Of California | Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility |
| US6376467B1 (en) | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| US6096288A (en) | 1998-10-12 | 2000-08-01 | Mobil Oil Corporation | Synthesis of the cubic mesoporous molecular sieve MCM-48 |
| WO2000030628A2 (en) | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
| US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
| US6541447B1 (en) | 1999-09-01 | 2003-04-01 | B & M Healthcare Technologies, Inc. | Wound healing composition and method for use thereof |
| NZ521437A (en) | 2000-02-25 | 2004-04-30 | Immunex Corp | Integrin antagonists suitable as inhibitors of angiogenesis |
| AU2001245945A1 (en) * | 2000-03-23 | 2001-10-03 | Pe Corporation (Ny) | Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof |
| US6582713B2 (en) | 2000-04-06 | 2003-06-24 | Univ. Of Colorado - Colorado Springs | Compositions and methods for promoting wound healing |
| US20100129332A1 (en) | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| CA2416788A1 (en) | 2000-07-31 | 2002-02-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
| US20030148924A1 (en) | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
| US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US6673603B2 (en) | 2000-09-01 | 2004-01-06 | Modex Therapeutiques, S.A. | Cell paste comprising keratinocytes and fibroblasts |
| GB2369572A (en) | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
| US20020119914A1 (en) | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
| JP2002198443A (ja) | 2000-12-26 | 2002-07-12 | Nec Corp | 半導体装置及びその製造方法 |
| GB0103877D0 (en) | 2001-02-16 | 2001-04-04 | King S College London | Novel Drug Delivery system |
| DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
| US6750234B2 (en) | 2001-03-08 | 2004-06-15 | University Of Kentucky Research Foundation | Methods for increasing leptin levels using nicotinic acid compounds |
| JP2002272831A (ja) | 2001-03-14 | 2002-09-24 | Fumio Kamiyama | 創傷被覆用粘着性シート |
| EP1385516A1 (en) | 2001-04-30 | 2004-02-04 | Arachnova Therapeutics Ltd. | The treatment of scarring and related conditions using ppar-gamma activators |
| AU2002319847A1 (en) | 2001-05-23 | 2002-12-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New nuclear receptor cofactors and related modulators |
| ES2184623B1 (es) | 2001-06-29 | 2004-09-16 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) | Piel artificial autologa secretora de leptina y metodo de obtencion. |
| US20030124503A1 (en) | 2001-12-28 | 2003-07-03 | Olivencia-Yurvati Albert H. | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
| WO2003059396A1 (en) | 2002-01-11 | 2003-07-24 | Sergei Zolotukhin | Adiponectin gene therapy |
| RU2249467C2 (ru) | 2002-11-25 | 2005-04-10 | ООО Научно-производственное предприятие "ЭРЛОН", Лтд. | Медицинский материал и изделия на его основе |
| US20040175384A1 (en) | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| US7960148B2 (en) * | 2003-07-02 | 2011-06-14 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
| AU2004259000A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| EP2228069A1 (en) | 2003-09-16 | 2010-09-15 | Garvan Institute Of Medical Research | Antagonists of protein kinase c-epsilon (pkcepsilon) and their use for the treatment of aberrant glucose metabolism associated therewith. |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20080206270A1 (en) * | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
| WO2006086681A2 (en) * | 2005-02-09 | 2006-08-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting smooth muscle cell migration and proliferation |
| EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
| WO2007016777A1 (en) * | 2005-08-05 | 2007-02-15 | Pharmagap Inc. | Targeted protein kinase c inhibitors and uses thereof |
| EP2452686A3 (en) | 2005-08-29 | 2012-09-05 | HealOr Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| US20090306045A1 (en) | 2005-12-22 | 2009-12-10 | Ira Mellman | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease |
| AU2007261399A1 (en) * | 2006-06-20 | 2007-12-27 | Metaproteomics, Llc | Reduced isoalpha acid based protein kinase modulation cancer treatment |
| CN102755649A (zh) | 2007-07-30 | 2012-10-31 | 希尔洛有限公司 | 药物组合物及相关方法 |
| US20110004955A1 (en) * | 2008-01-30 | 2011-01-06 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| CA2751156A1 (en) | 2009-02-24 | 2010-09-02 | Healor Ltd. | Visfatin therapeutic agents for the treatment of acne and other conditions |
-
2011
- 2011-01-11 EP EP11731747A patent/EP2523677A2/en not_active Withdrawn
- 2011-01-11 RU RU2012133148/15A patent/RU2012133148A/ru unknown
- 2011-01-11 CN CN2012103111308A patent/CN103083669A/zh active Pending
- 2011-01-11 RU RU2012134041/15A patent/RU2012134041A/ru unknown
- 2011-01-11 WO PCT/IL2011/000032 patent/WO2011083481A2/en not_active Ceased
- 2011-01-11 EP EP11731746.1A patent/EP2536421A4/en not_active Withdrawn
- 2011-01-11 JP JP2012548532A patent/JP2013516500A/ja not_active Withdrawn
- 2011-01-11 WO PCT/IL2011/000034 patent/WO2011083483A2/en not_active Ceased
- 2011-01-11 AU AU2011204425A patent/AU2011204425A1/en not_active Abandoned
- 2011-01-11 EP EP12008309.2A patent/EP2599494A1/en not_active Withdrawn
- 2011-01-11 CN CN2011800057108A patent/CN102724994A/zh active Pending
- 2011-01-11 CA CA2789972A patent/CA2789972A1/en not_active Abandoned
- 2011-01-11 WO PCT/IL2011/000033 patent/WO2011083482A2/en not_active Ceased
- 2011-01-11 CA CA2786854A patent/CA2786854A1/en not_active Abandoned
- 2011-07-13 US US13/181,687 patent/US8349793B2/en not_active Expired - Fee Related
-
2012
- 2012-12-10 US US13/709,727 patent/US20130274196A1/en not_active Abandoned
-
2013
- 2013-07-02 JP JP2013139038A patent/JP2013231052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011083483A3 (en) | 2011-11-17 |
| WO2011083482A2 (en) | 2011-07-14 |
| EP2536421A4 (en) | 2013-10-09 |
| CA2789972A1 (en) | 2011-07-14 |
| CN102724994A (zh) | 2012-10-10 |
| RU2012134041A (ru) | 2014-02-20 |
| CA2786854A1 (en) | 2011-07-14 |
| US20120190611A1 (en) | 2012-07-26 |
| US20130274196A1 (en) | 2013-10-17 |
| WO2011083482A3 (en) | 2012-03-08 |
| EP2536421A2 (en) | 2012-12-26 |
| US8349793B2 (en) | 2013-01-08 |
| WO2011083481A2 (en) | 2011-07-14 |
| WO2011083481A3 (en) | 2012-03-22 |
| CN103083669A (zh) | 2013-05-08 |
| EP2599494A1 (en) | 2013-06-05 |
| EP2523677A2 (en) | 2012-11-21 |
| RU2012133148A (ru) | 2014-02-20 |
| WO2011083483A2 (en) | 2011-07-14 |
| JP2013231052A (ja) | 2013-11-14 |
| JP2013516500A (ja) | 2013-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130274196A1 (en) | Method for treatment of inflammatory disease and disorder | |
| AU2020203183B2 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency | |
| US20250090624A1 (en) | Modulators of complement activity | |
| KR20200095485A (ko) | 보체 활성의 조절인자 | |
| WO2017201199A9 (en) | Compositions and methods for the treatment of prader-willi syndrome | |
| US20130296224A1 (en) | Method for treatment of inflammatory disease and disorder | |
| AU2012216534A1 (en) | Method for treatment of inflammatory disease and disorder | |
| JP2026508664A (ja) | 過剰炎症反応を抑制するタンパク質およびその応用 | |
| US20130296250A1 (en) | Method for treatment of psoriasis | |
| HK1170939A (en) | Method for treatment of inflammatory disease and disorder | |
| HK1179162A (en) | Method for treatment of inflammatory disease and disorder | |
| US20210113652A1 (en) | Maspin-based inhibition of osteoclast activity and promotion of bone formation | |
| US11771672B2 (en) | Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies | |
| US10512673B2 (en) | Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease | |
| HK40031446B (en) | Modulators of complement activity | |
| HK40031446A (en) | Modulators of complement activity | |
| WO2014041537A1 (en) | Protein kinase c (pkc) alpha inhibitors for treatment and prevention of toxicities caused by radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |